Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018

Sequencing of Therapy in Refractory mCRC

February 17th 2018

Management of Side Effects With TAS-102

February 17th 2018

Proactive Side Effect Management With Regorafenib

February 17th 2018

Clinical Implications of the ReDOS Findings

February 17th 2018

The Regorafenib Dose Optimization Study

February 17th 2018

Treatment Options in Refractory mCRC

February 17th 2018

Treatment Goals in Refractory mCRC

February 17th 2018

Expert Highlights Promising Research in mCRC and Other GI Cancers

February 17th 2018

Michael A. Morse, MD, discusses key trials that have broadened the treatment landscape of mCRC, and other ongoing developments in gastrointestinal cancers.

Lilly's Unique Reception Helps Attendees Step Into the Minds of People Living With GI Cancers

February 15th 2018

Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,

Dr. Bekaii-Saab on the Importance of the ReDOS Study in mCRC

February 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the importance of the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer (mCRC).

Dr. Morse on Managing Toxicities and Sequencing Agents in mCRC

February 12th 2018

Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, discusses factors that should be taken into consideration when sequencing agents in metastatic colorectal cancer.

Dr. Marshall on the Importance of Testing for BRAF Mutations in mCRC

February 12th 2018

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the specificity now required in the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

February 12th 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

Overman Highlights Latest Nivolumab Results in MSI-H/dMMR mCRC

February 8th 2018

Michael J. Overman, MD, discusses updated findings from the single-agent nivolumab CheckMate-142 cohort and combination data for nivolumab/ipilimumab from the pivotal trial.

Dr. Overman Discusses Immunotherapy and MSI Testing in CRC

February 8th 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy and microsatellite instability (MSI) testing in colorectal caner (CRC).

Alpelisib Active in PIK3CA-Altered Solid Tumors

February 8th 2018

Alpelisib (BYL719) induced a disease control rate of 58.2% and stable disease rate of 52.2% in patients with advanced solid tumors.

CRC: Deciding on Duration of Adjuvant Therapy

February 8th 2018

Antibody Selection and Tumor Sidedness in CRC

February 8th 2018